ArticleFood science and biotechnology2020
Probiotic treatment induced change of inflammation related metabolites in IBS-D patients/double-blind, randomized, placebo-controlled trial.
Article in Food science and biotechnology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05900752 (A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients), which is not on this map. Cited by 17 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Multi-Strain Probiotic Reduces the Frequency of Diarrhea in IBS-D Patients: A Two-Center, Randomized, Double-Blind, Placebo-controlled Study
Who cites it
17 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Effect of multistrain probiotics on symptom severity in irritable bowel syndrome: a systematic review and meta-analysis of irritable bowel syndrome-symptom severity score outcomes.European journal of gastroenterology & hepatology · 2026Pooled it
- Pooled it
- Fecal metabolomic analysis of the role of gut microbiota and short-chain fatty acids in the therapeutic mechanism of Timosaponin AIII in Sjögren's syndrome.Clinical rheumatology · 2025Article
- Navigating a challenging path: precision disease treatment with tailored oral nano-armor-probiotics.Journal of nanobiotechnology · 2025Review
- Exploring Gut Microbiota Imbalance in Irritable Bowel Syndrome: Potential Therapeutic Effects of Probiotics and Their Metabolites.Nutrients · 2024Review
- Propylene Glycol Alleviates Oxidative Stress and Enhances Immunity in Ketotic Cows through Modulating Amino Acid and Lipid Metabolism.Antioxidants (Basel, Switzerland) · 2024Article
- Article
- Exploration of associations among dietary tryptophan, microbiome composition and function, and symptom severity in irritable bowel syndrome.Neurogastroenterology and motility · 2023Article
- High Antioxidant Capacity ofFoods (Basel, Switzerland) · 2023Article
- What Has Longitudinal 'Omics' Studies Taught Us about Irritable Bowel Syndrome? A Systematic Review.Metabolites · 2023Review
- Golden bifid might improve diarrhea-predominant irritable bowel syndrome via microbiota modulation.Journal of health, population, and nutrition · 2022Article
- Low FODMAP Diet and Probiotics in Irritable Bowel Syndrome: A Systematic Review With Network Meta-analysis.Frontiers in pharmacology · 2022Review
- Article
- Probiotic properties of novel probioticFood science and biotechnology · 2021Article
- In Vivo Evaluation of Immune-Enhancing Activity of Red Gamju Fermented by ProbioticFoods (Basel, Switzerland) · 2021Article
- Anti-Inflammatory and Immunomodulatory Effects of Probiotics in Gut Inflammation: A Door to the Body.Frontiers in immunology · 2021Review
- Good microbes, bad genes? The dissemination of antimicrobial resistance in the human microbiome.Gut microbesReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
There have been many studies suggesting that probiotics are effective in patients with diarrhea-predominant irritable bowel syndrome (IBS-D). However, its mechanism of action as well as prediction of response is still to be elucidated. In the present study, to find out metabolomic characteristics of probiotic effect in IBS-D, we compared IBS symptom changes and metabolomic characteristics in the subjects' urine samples between multi-strain probiotics (one strain of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.